Apraclonidine (INN), also known under the brand name Iopidine, is a sympathomimetic used in glaucoma therapy. It is an α2 adrenergic receptor agonist and a weak α1 adrenergic receptor agonist. Apraclonidine is formulated for topical ocular use in concentrations commonly 0.5 percent for short term prophylaxis and 1 percent for acute intraocular pressure reduction. Pharmacologically it reduces aqueous humor production through presynaptic α2 receptor activation in the ciliary epithelium and may modestly increase uveoscleral outflow. Onset of action is typically within 20 to 30 minutes with peak effect in about one to two hours and clinically useful duration up to several hours depending on concentration and patient response. The sterile ophthalmic solutions typically contain a quaternary ammonium preservative such as benzalkonium chloride; products must meet sterility and particulate limits and are supplied in single or multiuse dropper bottles with instructions for storage at controlled room temperature. Systemic absorption is limited but can produce centrally mediated effects in sensitive patients; common local adverse reactions include ocular allergy and follicular conjunctivitis with repeated use, making apraclonidine preferable for short term or procedural use rather than chronic long term therapy.
Parent: Apraclonidine Hydrochloride
Parent: Apraclonidine
Parent: Apraclonidine
The impurity profile for apraclonidine drug substance and finished ophthalmic solutions is routinely monitored by validated HPLC or LC-MS methods with limits set to control individual related substances and total impurities to meet pharmacopeial quality expectations. Typical internal specification ranges used by manufacturers and quality control laboratories set individual related compound limits in the low subpercent range, for example not greater than about 0.1 to 0.5 percent for a single unidentified impurity and a combined total impurity limit generally maintained below about 0.5 to 1.0 percent, depending on the method and regulatory guidance applied. Known related compounds and degradants observed in stability and forced-degradation studies include debrominated or dehalogenated analogs, N-oxide and N-dealkylation products of the imidazoline nucleus, hydrolysis products from imidazoline opening, and low-level synthesis residuals such as precursor amines; residual solvents and preservative content are controlled separately to established limits. Routine quality control monitors these species and specifies acceptance criteria, and manufacturers document impurity identification and qualification when levels approach reporting thresholds.
Apraclonidine is used primarily to prevent or reduce short term intraocular pressure spikes, for example after laser trabeculoplasty or intraocular surgery, and to provide short term control of acute IOP elevations. It is also used diagnostically in ophthalmology, for example in pharmacologic testing for Horner syndrome.
Apraclonidine is not classified as a mydriatic agent, but because it has weak α1 adrenergic activity it can produce mild to moderate pupil dilation in some patients. The mydriatic effect is variable and is not the drug’s primary therapeutic action.
Apraclonidine activates presynaptic α2 adrenergic receptors in the ciliary body to reduce norepinephrine release and thereby decrease aqueous humor production; it may also modestly enhance uveoscleral outflow. The net result is a reduction in intraocular pressure.
Apraclonidine can dilate the pupil in certain individuals because of its weak α1 receptor agonism, but dilation is generally less pronounced than with standard mydriatics and is unpredictable, so apraclonidine is not relied upon for pupil dilation in clinical practice.
